Medications Development for Opioid Abuse

被引:15
|
作者
Negus, S. Stevens [1 ]
Banks, Matthew L. [1 ]
机构
[1] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA
来源
基金
美国国家卫生研究院;
关键词
PRECIPITATED WITHDRAWAL SIGNS; HEROIN-DEPENDENT INDIVIDUALS; BEHAVIORAL ECONOMIC-ANALYSIS; MORPHINE-WITHDRAWAL; OPIATE WITHDRAWAL; NALOXONE; FOOD; BUPRENORPHINE; CHOICE; NALTREXONE;
D O I
10.1101/cshperspect.a012104
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Here we describe methods for preclinical evaluation of candidate medications to treat opioid abuse and dependence. Our perspective is founded on the propositions that (1) drug self-administration procedures provide the most direct method for assessment of medication effects, (2) procedures that assess choice between opioid and nondrug reinforcers are especially useful, and (3) the states of opioid dependence and withdrawal profoundly influence both opioid reinforcement and the effects of candidate medications. Effects of opioid medications on opioid choice in nondependent and opioid-dependent subjects are reviewed. Various nonopioid medications have also been examined, but none yet have been identified that safely and reliably reduce opioid choice. Future research will focus on (1) strategies for increasing safetyand/or effectiveness of opioid medications, and (2) continued development of nonopioids such as inhibitors of endocannabinoid catabolic enzymes or inhibitors of opioid-induced glial activation.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] ABUSE POTENTIAL OF VARIOUS OPIOID MEDICATIONS
    BROOKOFF, D
    JOURNAL OF GENERAL INTERNAL MEDICINE, 1993, 8 (12) : 688 - 690
  • [2] OPIOID USE AND ABUSE ARE ASSOCIATED WITH USE OF SEDATIVE HYPNOTIC MEDICATIONS
    Tubbs, Andrew
    Naps, Michelle
    Grandner, Michael
    Rivera, Louis
    SLEEP, 2021, 44 : A140 - A140
  • [3] Medications development for treating drug abuse
    Bidlack, Jean M.
    Mathews, Jennifer L.
    Cohen, Dana J.
    Knapp, Brian I.
    ACTA PHARMACOLOGICA SINICA, 2006, 27 : 15 - 15
  • [4] Medications Development for Treatment of Opioid Use Disorder
    Townsend, E. Andrew
    Negus, S. Stevens
    Banks, Matthew L.
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2021, 11 (01): : 1 - 26
  • [5] Formulation considerations for the development of medications with abuse potential
    Mansbach, Robert S.
    Moore, Richard A., Jr.
    DRUG AND ALCOHOL DEPENDENCE, 2006, 83 : S15 - S22
  • [6] Clinical and pathologic characteristics of intranasal abuse of combined opioid-acetaminophen medications
    Vosler, Peter S.
    Ferguson, Berrylin J.
    Contreras, Jorge I.
    Wang, Eric W.
    Schaitkin, Barry M.
    Lee, Stella
    INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY, 2014, 4 (10) : 839 - 844
  • [7] Development of opioid formulations with limited diversion and abuse potential
    Fudala, PJ
    Johnson, RE
    DRUG AND ALCOHOL DEPENDENCE, 2006, 83 : S40 - S47
  • [8] ABUSE OF DRUG MEDICATIONS
    HOOD, J
    NEW YORK STATE JOURNAL OF MEDICINE, 1971, 71 (13) : 1677 - &
  • [9] Prescription Opioid Abuse in Chronic Pain: A Review of Opioid Abuse Predictors and Strategies to Curb Opioid Abuse
    Sehgal, Nalini
    Manchikanti, Laxmaiah
    Smith, Howard S.
    PAIN PHYSICIAN, 2012, 15 (03) : ES67 - ES92
  • [10] THE IMPACT OF REFORMULATED OXYCONTIN® IN AUSTRALIA: KEY FINDINGS FROM THE NATIONAL OPIOID MEDICATIONS ABUSE DETERRENCE
    Larance, Briony
    Ali, Robert
    Farrell, Michael
    Peacock, Amy
    Bruno, Raimondo
    Lintzeris, Nicholas
    Dobbins, Timothy
    Degenhardt, Louisa
    DRUG AND ALCOHOL REVIEW, 2016, 35 : 47 - 47